An observational study in Cardiovascular Diseases, Coronary Artery Disease and Heart Diseases, sponsored by Roland von Känel. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Roland von Känel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 34th largest by planned enrollment of the 52 observational ones that give a count, is one of 6 that started in 2024, is one of 52 observational ones, reaches primary completion later than 16 of the 40 other live ones, and was the 164th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Switzerland, Germany
Ages 18+
IGLESIAS Juan Fernando · Sites in Switzerland
Ages 18+
Translumina GmbH · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 17 · Phase 4 25
First in 2002; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is close to the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 296 across the 125 interventional studies, 992 across the 52 observational. Of the 114 that completed or were terminated, 25 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 177 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Roland von Känel as lead sponsor.
Roland von Känel has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Artery Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04988685Luzerner KantonsspitalSIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters | 2026-12-31 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06706323Roland von KänelDepressive Symptoms After Cardiac Surgery | 2027-04-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary goal of this project is to develop a predictive model for clinically significant depressive symptoms (CSDS) in patients undergoing coronary artery bypass graft (CABG) surgery, using pre- and perioperative data. CSDS occur in about 30 percent of CABG patients, which is four times higher than in the general population. These symptoms are linked to poor quality of life and increased morbidity and mortality. The aim is to create a model that can identify patients at risk for postoperative depression. This tool could help clinicians make informed decisions and take preventive measures to manage depression after surgery.
In patients undergoing coronary artery bypass graft (CABG) surgery, the prevalence of clinically significant depressive symptoms (CSDS) is about 30 percent, four times higher than the 12-month prevalence in the general population. CSDS are associated with poor quality of life and increased morbidity and mortality. While several predictors of post-CABG CSDS have been identified, no prognostic model exists.
The aim of this project is to develop a predictive model for post-surgery CSDS in CABG patients using pre- and perioperative data. A prognostic prediction model for CSDS 6 weeks post-CABG, will be developed using demographic, psychometric, medical, inflammation, and cardiac interoception data. Machine learning algorithms will be employed for data analysis. A cohort of 350 participants from two hospitals will be recruited, with 300 participants expected to complete the study. Data will be divided into training (200 participants) and testing (100 participants) sets. Nested cross-validation will prevent overfitting. Both binary and regression prediction models will be used. Additionally, a simpler model will be developed to increase generalizability.
The prediction model will identify CABG patients at risk of post-surgery CSDS. The model will help identify patients at risk for CSDS before surgery, enabling early interventions. Clinicians can make precision medicine decisions to prevent or manage CSDS, improving postoperative psychological well-being. Additionally, the study could advance understanding of the mechanisms linking depression and coronary heart disease, particularly in relation to inflammation and interoception.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
This study's planned enrollment of 300 is close to the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →This is the only study on the registry with Roland von Känel as lead sponsor.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study will include 300 patients undergoing coronary artery bypass graft (CABG) surgery, recruited from two hospitals: the University Hospital Zurich (USZ) and the Municipal Hospital of Zurich - Triemli. Of these, 200 patients will be in the training group and 100 in the test group for developing and validating a predictive model for post-surgery depressive symptoms. Participants will be recruited consecutively, with inclusive criteria regarding sex and an upper age limit of 90 years to enhance eligibility and generalizability. As no literature suggests differences in depressive symptoms based on surgery type, patients will be included regardless of whether their CABG is isolated or combined with valve intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From the final cohort of 300 participants, 200 will be recruited at Hospital I (University Hospital Zurich) to form the training group for developing the optimal statistical model.
From the final cohort of 300 participants, the remaining 100 will be recruited at Hospital II (Stadtspital Zurich Triemli) to form the test group for validating the final model.
Patient Health Questionnaire (PHQ-9) score ≥10 (yes/no) at 6 weeks post-CABG
The Patient Health Questionnaire (PHQ)-9 will assess the severity of self-rated depressive symptoms over the last two weeks. It covers the nine Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria for major depression, with symptoms rated on a 4-point Likert scale. Scores range from 0 to 27, with higher scores indicating more severe symptoms. A score of 10 or higher corresponds to a diagnosis of depression, with 88 percent sensitivity and specificity. As the best cut-off for post-CABG CSDS is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. One approach frames the prediction challenge as a binary classification problem and uses a PHQ-9 cut-off score ≥10 for defining the presence versus absence of CSDS.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
PHQ-9 score continuous at 6 weeks post-CABG
The PHQ-9 will assess the severity of self-rated depressive symptoms over the last two weeks. It covers the nine DSM-5 criteria for major depression, with symptoms rated on a 4-point Likert scale. Scores range from 0 to 27, with higher scores indicating more severe symptoms. A score of 10 or higher corresponds to a diagnosis of depression, with 88 percent sensitivity and specificity. As the best cut-off for post-CABG CSDS is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. The second approach views the prediction challenge as a regression problem and tries to predict individual PHQ-9 scores without applying any threshold.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
General Anxiety Disorder (GAD-7) score ≥10 (yes/no) at 6 weeks post-CABG
The General Anxiety Disorder (GAD)-7 questionnaire will assess self-rated anxiety symptoms over the past two weeks. Seven items are rated on a 4-point Likert scale, with total scores ranging from 0 to 21. A score of 10 or higher indicates moderate to severe anxiety, corresponding to a GAD diagnosis with 89% sensitivity and 82% specificity. As the best cut-off for post-CABG GAD is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. One approach frames the prediction challenge as a binary classification problem and uses a GAD-7 cut-off score ≥10 for defining the presence versus absence of GAD.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
GAD-7 score continuous at 6 weeks post-CABG
The GAD-7 questionnaire will assess self-rated anxiety symptoms over the past two weeks. Seven items are rated on a 4-point Likert scale, with total scores ranging from 0 to 21. A score of 10 or higher indicates moderate to severe anxiety, corresponding to a GAD diagnosis with 89% sensitivity and 82% specificity. As the best cut-off for post-CABG GAD is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. The second approach views the prediction challenge as a regression problem and tries to predict individual GAD-7 scores without applying any threshold.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
PTSD (Post-traumatic Stress Disorder) Checklist for DSM-5 (PCL-5) score ≥33 at 6 weeks post-CABG
The PTSD Checklist for DSM-5 (PCL-5) will assess CABG surgery-induced posttraumatic stress. It is a 20-item self-report measure evaluating the DSM-5 PTSD symptoms over the past month. Items are rated on a 5-point Likert scale, with scores of 33 or higher indicating probable PTSD. As the best cut-off for post-CABG PTSD is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. One approach frames the prediction challenge as a binary classification problem and uses a PCL-5 cut-off score ≥33 for defining the presence versus absence of PTSD.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
PCL-5 score continuous at 6 weeks post-CABG
The PCL-5 will assess CABG surgery-induced posttraumatic stress. It is a 20-item self-report measure evaluating the DSM-5 PTSD symptoms over the past month. Items are rated on a 5-point Likert scale, with scores of 33 or higher indicating probable PTSD. As the best cut-off for post-CABG PTSD is difficult to determine a priori for a prediction model, a two complementary approaches for the analysis will be used, correcting for multiple tests when assessing the significance of the accuracy of the prediction model. The second approach views the prediction challenge as a regression problem and tries to predict individual PCL-5 scores without applying any threshold.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
Short-Form Health Survey-12 (SF-12) mental health component score at 6 weeks post-CABG
The Short-Form Health Survey (SF-12) will assess physical and mental health-related quality of life (QoL) over the last four weeks, covering aspects such as physical functioning, pain, vitality, social functioning, and mental health.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
SF-12 physical health component score at 6 weeks post-CABG
The SF-12 will assess physical and mental health-related quality of life (QoL) over the last four weeks, covering aspects such as physical functioning, pain, vitality, social functioning, and mental health.
Time frame: Baseline (1 day before CABG surgery) and Follow Up (6 weeks after CABG surgery)
Plan to share: Undecided
Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 28 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.